Catalyst overview
Research summary
This catalyst tracks a Phase 1b data readout for Ziftomenib + venetoclax/azacitidine in Acute myeloid leukemia. The expected timing is based on the latest available company guidance and may change.
KOMET-007 trial. 1/30/24- Initial data from 20 patients. 2/26/25- Present prelim data at medical meeting in H2 2025. 11/3/25- Present results at ASH'25 on December 8, 2025. 12/08/25:- Demonstrated 86% CRc in newly diagnosed NPM1-mutated AML and strong activity in relapsed/refractory disease. 01/11/26:- Plan to publish ven/aza combination data in R/R NPM1-m AML in H1 2026. 03/05/26:- Plan to publish ziftomenib plus venetoclax/azacitidine data in R/R NPM1-m AML in H1 2026. 05/12/26:- EHA poster PF537 on June 12, 2026 includes ven/aza combo exposure-response analysis. 05/12/26:- Plan H1 2026 publication of ziftomenib plus venetoclax/azacitidine R/R NPM1-m AML data; EHA poster June 12. 06/02/26:- Blood published updated KOMET-007 R/R NPM1-m AML ven/aza results; 87% ORR, 70% CRc. 08/12/26:- Updated KOMET-007 ven/aza data are expected in H2 2026.
Verification
Confirm timing and program details against the company announcement or filing.